PharmaJet Presents Multiple Partners’ Data Demonstrating Superior Immunogenicity With Their Needle-free Systems at BIO International Convention
Growing number of partners using needle-free to enhance vaccine effectiveness
GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet®, a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, today announced that their latest research results were presented at the BIO International Convention in June. The presentation, entitled Improved Vaccine and Therapeutic Performance…without the Jab, was presented by Paul LaBarre, MS, MBA, Vice President Global Business Development at PharmaJet, Inc.
There is a growing body of evidence that shows needle-free delivery can make injectables perform better. PharmaJet's Needle-free Injection Systems (NFIS) can improve performance by providing a similar, and often better, immunogenicity in the patient with a strong antibody and T-cell response, when used to administer nucleic acid-based vaccines and therapeutics. Currently there are 18 partner publications that show equivalent or better effectiveness when using the PharmaJet NFIS compared with either electroporation or traditional needle and syringe. These include 11 studies comparing delivery methods for DNA vaccines, 1 for an mRNA vaccine, and 2 for live attenuated vaccines.1
This presentation highlighted published collaborator data from three partners that found increased immunogenicity when using the PharmaJet Systems to deliver nucleic acid-based vaccines:
- Zydus Lifesciences recently conducted a non-human primate study on their Plasmid DNA-based COVID-19 vaccine. They saw higher antibody responses with the Tropis® ID System as compared to needle and syringe delivery and better protection from challenge with the virus. After getting similar results in their phase I studies, they progressed to phase II and III exclusively using PharmaJet’s Needle-free Systems and are now commercializing their product.2
- INRA compared the results of DNA plasmids administered with needle-free jet injection or electroporation. The Tropis System induced higher luciferase expression, was more potent to transduce skin cells and induced lower inflammatory responses.3
- Curevac compared needle and syringe versus needle-free delivery at both ID (using the PharmaJet Tropis® System) and IM (using the PharmaJet Stratis® System) depths for their candidate mRNA-based vaccine that encodes rabies antigen and found the candidate vaccine boosted functional antibodies when humans were injected with a needle-free device but not when injected by a needle-syringe.4
“Our worldwide partner list is quickly growing, and feedback has been very positive,” said Chris Cappello, President and Chief Executive Officer, PharmaJet, Inc. “With over 80 studies currently in progress with 55 pharmaceutical partners, we’ve learned that a broad variety of pharmaceutical products can be delivered needle-free including nucleic acid-based, inactivated, subunit, live attenuated and viral vector vaccines. We are aiming to increase our pipeline 3-fold in the next several years.”
For more information about PharmaJet visit www.pharmajet.com.
Refer to Instructions for Use to ensure safe injections and to review risks.
1 Data on file
2 Momin, et al 2021, Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India
PharmaJet’s mission is to enable greater access to life improving pharmaceuticals. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit www.pharmajet.com. Follow us on LinkedIn.
About the BIO International Convention
The 2022 BIO International Convention featured 100+ interactive sessions across 4 days covering a variety of therapeutic areas, business development, digital health, patient advocacy, public policy, and next-generation biotherapeutics, and the latest updates from industry experts on COVID-19 and the vaccine.
1-888-900-4321 Option 3